In this study of 162 patients with BRAF V600 mutated metastatic melanoma, the combination of dabrafenib and trametinib at 2 mg had an improved median PFS at 9.4 months, compared with 5.8 months in the dabrafenib monotherapy group. The gene discussed is BRAF; the disease is metastatic melanoma.